Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium
Biora Therapeutics (Nasdaq: BIOR), a biotech company focused on reimagining therapeutic delivery, has announced its participation in the 19th Annual Peptide Therapeutics Symposium. The event will take place both virtually and in-person in La Jolla, California, from October 22-23, 2024.
Dr. Sharat Singh, Head of Research at Biora Therapeutics, will deliver a presentation titled 'Empowering Peptide Self-Administration with Needle Free Smart Capsules' on October 22, 2024, from 2:30 PM to 3:00 PM PT.
The Peptide Therapeutics Symposium is a prestigious gathering of world leaders in peptide research from academia and biopharmaceutical industries. It focuses on advancements in core technology relevant to peptide-based drug discovery and therapeutic candidate development.
Biora Therapeutics (Nasdaq: BIOR), un'azienda biotech focalizzata sulla ridefinizione della somministrazione terapeutica, ha annunciato la sua partecipazione al 19° Simposio Annuale sulle Terapie Peptidiche. L'evento si svolgerà sia virtualmente che di persona a La Jolla, California, dal 22 al 23 ottobre 2024.
Il Dr. Sharat Singh, Responsabile della Ricerca di Biora Therapeutics, presenterà un intervento dal titolo 'Potenziare l'Auto-somministrazione dei Peptidi con Capsule Intelligenti Senza Ago' il 22 ottobre 2024, dalle 14:30 alle 15:00 PT.
Il Simposio sulle Terapie Peptidiche è un'importante riunione di esperti di fama mondiale nella ricerca sui peptidi provenienti dal mondo accademico e dall'industria biofarmaceutica. Si concentra sui progressi nelle tecnologie fondamentali rilevanti per la scoperta di farmaci a base di peptidi e nello sviluppo di candidati terapeutici.
Biora Therapeutics (Nasdaq: BIOR), una compañía biotecnológica enfocada en reinventar la entrega terapéutica, ha anunciado su participación en el 19° Simposio Anual sobre Terapias Peptídicas. El evento se llevará a cabo tanto de manera virtual como presencial en La Jolla, California, del 22 al 23 de octubre de 2024.
El Dr. Sharat Singh, Jefe de Investigación de Biora Therapeutics, presentará una charla titulada 'Potenciando la Auto-administración de Péptidos con Cápsulas Inteligentes sin Aguja' el 22 de octubre de 2024, de 2:30 PM a 3:00 PM PT.
El Simposio sobre Terapias Peptídicas es una reunión prestigiosa de líderes mundiales en investigación de péptidos provenientes de la academia y de la industria biofarmacéutica. Se centra en los avances en la tecnología fundamental relevante para el descubrimiento de fármacos basados en péptidos y el desarrollo de candidatos terapéuticos.
비오라 테라퓨틱스(Biora Therapeutics) (Nasdaq: BIOR)는 치료 전달 방식을 재구상하는 생명공학 회사로서, 제19회 연례 펩타이드 치료 심포지엄에 참여한다고 발표했다. 이 행사는 2024년 10월 22일부터 23일까지 캘리포니아 롤라호에서 온라인과 오프라인으로 진행된다.
비오라 테라퓨틱스의 연구 책임자인 샤라트 싱(Dr. Sharat Singh)은 2024년 10월 22일 오후 2:30부터 3:00까지 '바늘 없는 스마트 캡슐로 펩타이드 자가 투여 강화하기'라는 제목으로 발표를 진행할 예정이다.
펩타이드 치료 심포지엄은 학계와 생물 제약 산업의 세계적 권위자들이 모이는 권위 있는 행사이다. 이 심포지엄은 펩타이드 기반 의약품 발견 및 치료 후보 개발과 관련된 핵심 기술의 발전에 중점을 두고 있다.
Biora Therapeutics (Nasdaq: BIOR), une entreprise biopharmaceutique axée sur la réimagination de la livraison thérapeutique, a annoncé sa participation au 19ème Symposium Annuel sur les Thérapies Peptidiques. L'événement se déroulera à la fois virtuellement et en personne à La Jolla, Californie, du 22 au 23 octobre 2024.
Le Dr Sharat Singh, Responsable de la Recherche chez Biora Therapeutics, donnera une présentation intitulée 'Renforcer l'Auto-administration des Peptides avec des Capsules Intelligentes sans Aiguille' le 22 octobre 2024, de 14h30 à 15h00 PT.
Le Symposium sur les Thérapies Peptidiques est un rassemblement prestigieux de leaders mondiaux dans la recherche sur les peptides, issus du milieu académique et de l'industrie biopharmaceutique. Il se concentre sur les avancées technologiques fondamentales pertinentes pour la découverte de médicaments basés sur les peptides et le développement de candidats thérapeutiques.
Biora Therapeutics (Nasdaq: BIOR), ein Biotechnologie-Unternehmen, das sich auf die Neugestaltung der therapeutischen Lieferung konzentriert, hat seine Teilnahme am 19. jährlichen Symposium über Peptidtherapien angekündigt. Die Veranstaltung findet sowohl virtuell als auch persönlich in La Jolla, Kalifornien, vom 22. bis 23. Oktober 2024 statt.
Dr. Sharat Singh, Leiter der Forschung bei Biora Therapeutics, wird am 22. Oktober 2024 von 14:30 bis 15:00 Uhr PT einen Vortrag mit dem Titel 'Peptid-Autoanwendung mit nadellosen Smart-Kapseln stärken' halten.
Das Symposium über Peptidtherapien ist ein prestigeträchtiges Treffen von weltweit führenden Wissenschaftlern in der Peptidforschung aus der Akademie und der biopharmazeutischen Industrie. Es konzentriert sich auf Fortschritte in der Grundtechnologie, die für die Entdeckung von Arzneimitteln auf Peptidbasis und die Entwicklung therapeutischer Kandidaten relevant ist.
- None.
- None.
SAN DIEGO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will present at the 19th Annual Peptide Therapeutics Symposium, taking place virtually and in person in La Jolla, California, October 22–23, 2024. Details of the presentation are as follows:
| Presentation Title: | Empowering Peptide Self-Administration with Needle Free Smart Capsules |
| Date & Time: | October 22, 2024, 2:30 PM – 3:00 PM PT |
| Presenter: | Sharat Singh, PhD, Head of Research, Biora Therapeutics |
The Peptide Therapeutics Symposium brings together world leaders in peptide research from academia and the biopharmaceutical industries who are focused on advances in core technology pertinent to peptide-based drug discovery and therapeutic candidate development.
About Biora Therapeutics
Biora Therapeutics is a clinical-stage biotech company developing two smart pill-based therapeutics platforms: the NaviCap™ platform for colon-targeted treatment of IBD, designed to improve patient outcomes through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ platform for oral delivery of large molecules, designed to replace injection with needle-free, oral delivery for better management of chronic diseases.
For more information, visit bioratherapeutics.com or follow the company on LinkedIn or X.
Safe Harbor Statement or Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development, preclinical and clinical trial activities, including those involving BT-600 and our NaviCap platform and model-based data projections for the BT-600 program, and partnering and collaboration efforts with third parties, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “envision,” “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “anticipate,” “forward,” “believe,” “design,” “estimate,” “predict,” “projects,” “projecting,” “potential,” “plan,” “goal(s),” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future FDA filings and initiate and execute clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators or partners, our ability to raise sufficient capital to achieve our business objectives, our ability to maintain our listing on the Nasdaq Global Market, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) and other subsequent documents, including Quarterly Reports on Form 10-Q, that we file with the SEC.
Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
IR@bioratherapeutics.com
(646) 627-8390
Media Contact
Liz Robinson
CG Life
lrobinson@cglife.com
FAQ
When and where is Biora Therapeutics (BIOR) presenting at the Peptide Therapeutics Symposium?
What is the title of Biora Therapeutics' (BIOR) presentation at the 2024 Peptide Therapeutics Symposium?
Who will be presenting on behalf of Biora Therapeutics (BIOR) at the 2024 Peptide Therapeutics Symposium?
What is the focus of the Peptide Therapeutics Symposium that Biora Therapeutics (BIOR) is attending?
